DK1272177T3 - Fremgangsmåde og formulering til behandling af resistens over for antihypertensiva og forbundne tilstande - Google Patents

Fremgangsmåde og formulering til behandling af resistens over for antihypertensiva og forbundne tilstande

Info

Publication number
DK1272177T3
DK1272177T3 DK00900110T DK00900110T DK1272177T3 DK 1272177 T3 DK1272177 T3 DK 1272177T3 DK 00900110 T DK00900110 T DK 00900110T DK 00900110 T DK00900110 T DK 00900110T DK 1272177 T3 DK1272177 T3 DK 1272177T3
Authority
DK
Denmark
Prior art keywords
formulation
resistance
treatment
melatonin
associated conditions
Prior art date
Application number
DK00900110T
Other languages
Danish (da)
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of DK1272177T3 publication Critical patent/DK1272177T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00900110T 2000-01-05 2000-01-05 Fremgangsmåde og formulering til behandling af resistens over for antihypertensiva og forbundne tilstande DK1272177T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000009 WO2001049286A1 (en) 2000-01-05 2000-01-05 Method and formulation for treating resistance to antihypertensives and related conditions

Publications (1)

Publication Number Publication Date
DK1272177T3 true DK1272177T3 (da) 2007-08-06

Family

ID=11042938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00900110T DK1272177T3 (da) 2000-01-05 2000-01-05 Fremgangsmåde og formulering til behandling af resistens over for antihypertensiva og forbundne tilstande

Country Status (31)

Country Link
US (3) US7332177B1 (ja)
EP (1) EP1272177B1 (ja)
JP (1) JP4996803B2 (ja)
CN (1) CN1414851A (ja)
AT (1) ATE359072T1 (ja)
AU (1) AU782266B2 (ja)
BG (1) BG65637B1 (ja)
BR (1) BR0016918A (ja)
CA (1) CA2396129C (ja)
CY (2) CY1108018T1 (ja)
CZ (1) CZ299931B6 (ja)
DE (1) DE60034373T2 (ja)
DK (1) DK1272177T3 (ja)
EA (1) EA004679B1 (ja)
EE (1) EE200200379A (ja)
ES (1) ES2284471T3 (ja)
HK (1) HK1052655A1 (ja)
HU (1) HU227002B1 (ja)
IL (1) IL150190A0 (ja)
IS (1) IS6439A (ja)
MX (1) MXPA02005783A (ja)
NO (1) NO322567B1 (ja)
NZ (1) NZ520078A (ja)
PL (1) PL201219B1 (ja)
PT (1) PT1272177E (ja)
SI (1) SI1272177T1 (ja)
SK (1) SK287508B6 (ja)
TR (1) TR200201724T2 (ja)
TW (1) TWI260983B (ja)
UA (1) UA77394C2 (ja)
WO (1) WO2001049286A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP3964417B2 (ja) * 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
US20130325151A1 (en) * 2010-10-25 2013-12-05 Uico, Llc Control system with solid state touch sensor for complex surface geometry
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
WO2018033546A1 (en) * 2016-08-18 2018-02-22 Koninklijke Philips N.V. Blood-pressure management
HUE051362T2 (hu) 2016-10-31 2021-03-01 Neurim Pharma 1991 Melatonin minitabletták és eljárás azok elõállítására
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
ES2724933A1 (es) * 2018-03-13 2019-09-17 Ocupharm Diagnostics Sl Terapia combinada con melatonina para la reducción de la presión intraocular
GB2617102A (en) * 2022-03-29 2023-10-04 John Hemming Trading Ltd Sleep therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518468B1 (en) 1991-05-09 1999-06-30 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
US5508039A (en) 1991-10-18 1996-04-16 Alza Corporation Controlled transdermal administration of melatonin
US5646049A (en) * 1992-03-27 1997-07-08 Abbott Laboratories Scheduling operation of an automated analytical system
DK0565296T3 (da) * 1992-04-07 1996-12-09 Neurim Pharma 1991 Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
EP0664339A4 (en) * 1993-07-09 1999-04-28 Wakunaga Seiyaku Kk METHOD FOR DISCRIMINATION OF NUCLEIC ACIDS AND TEST KIT FOR THIS PURPOSE.
SK284521B6 (sk) 1995-02-01 2005-05-05 Neurim Pharmaceuticals (1991) Ltd. Použitie melatonínu na prípravu farmaceutického prostriedku
US5648727A (en) * 1995-10-24 1997-07-15 Dpc Cirrus Inc. Capacitive level sensing pipette probe
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
WO1997037670A1 (en) * 1996-04-10 1997-10-16 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии

Also Published As

Publication number Publication date
BG106978A (en) 2003-03-31
HU227002B1 (en) 2010-04-28
CN1414851A (zh) 2003-04-30
WO2001049286A1 (en) 2001-07-12
BR0016918A (pt) 2004-03-23
CZ20022346A3 (cs) 2002-11-13
NO20023102D0 (no) 2002-06-27
CY2007033I1 (el) 2009-11-04
TR200201724T2 (tr) 2003-03-21
CA2396129A1 (en) 2001-07-12
DE60034373D1 (de) 2007-05-24
CY1108018T1 (el) 2011-04-06
PT1272177E (pt) 2007-07-11
SK287508B6 (sk) 2010-12-07
IS6439A (is) 2002-06-24
AU782266B2 (en) 2005-07-14
CZ299931B6 (cs) 2008-12-29
CA2396129C (en) 2010-11-30
CY2007033I2 (el) 2009-11-04
JP4996803B2 (ja) 2012-08-08
US20120070501A1 (en) 2012-03-22
EP1272177A1 (en) 2003-01-08
ES2284471T3 (es) 2007-11-16
EE200200379A (et) 2003-10-15
AU1888200A (en) 2001-07-16
NO20023102L (no) 2002-08-30
EA004679B1 (ru) 2004-06-24
MXPA02005783A (es) 2003-10-14
PL201219B1 (pl) 2009-03-31
DE60034373T2 (de) 2007-12-20
NO322567B1 (no) 2006-10-30
US8075914B2 (en) 2011-12-13
SI1272177T1 (sl) 2007-10-31
PL356325A1 (en) 2004-06-28
HUP0204089A3 (en) 2005-12-28
ATE359072T1 (de) 2007-05-15
UA77394C2 (uk) 2006-12-15
BG65637B1 (bg) 2009-04-30
EA200200738A1 (ru) 2002-12-26
HK1052655A1 (zh) 2003-09-26
TWI260983B (en) 2006-09-01
IL150190A0 (en) 2002-12-01
JP2003519181A (ja) 2003-06-17
EP1272177B1 (en) 2007-04-11
US7332177B1 (en) 2008-02-19
NZ520078A (en) 2004-02-27
SK9732002A3 (en) 2002-11-06
US8728511B2 (en) 2014-05-20
US20080085317A1 (en) 2008-04-10
HUP0204089A2 (hu) 2003-04-28
EP1272177A4 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
DK1272177T3 (da) Fremgangsmåde og formulering til behandling af resistens over for antihypertensiva og forbundne tilstande
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK1404331T3 (da) Sustained release-formuleringer af oxymorphon
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
MXPA02000282A (es) Composiciones de cuidado personal.
IS2455B (is) Meðferðarsamsetningar úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
DE60035574D1 (de) Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
TW200509998A (en) Controlled release of highly soluble agents
HUP0100844A2 (hu) Az azithromycin szöveti behatolásának és biológiai hasznosulásának növelésére szolgáló eljárás
DK1267847T3 (da) 5HT2-antagonist til regulering af IOP og behandling af glaucom
EE200400074A (et) Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
TW200637604A (en) Cosmetic compositions containing sophora alopecuroides L. extracts
WO2004087105A8 (en) Combination formulations of platinum agents and fluoropyrimidines
IL179040A0 (en) Methods of using and compositions comrpising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
BR0003648A (pt) Composições e métodos para tratar condições alérgicas e inflamatórias com tosse
NO20030483D0 (no) Assosiasjoner av dalfopristin/quinupristin med cefpirom